- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01551056
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
October 6, 2017 updated by: Aciex Therapeutics, Inc.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
91
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- ORA, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- positive bilateral conjunctival allergen challenge (CAC) reaction
Exclusion Criteria:
- known contraindications or sensitivities to the study medication or its components
- any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters
- use of disallowed medication during the period indicated prior to the enrollment or during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AC-170 0.24%
|
1 drop in each eye at 2 separate times during a 14 day period
|
PLACEBO_COMPARATOR: AC-170 0%
|
1 drop in each eye at 2 separate times during a 14 day period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular Itching at Onset of Action (15 Minutes Post-dose)
Time Frame: 3, 5, 7 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of ocular itching score over both eyes was analyzed.
|
3, 5, 7 minutes post-CAC
|
Conjunctival Redness at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of conjunctival redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 3, 5, 7 minutes post-CAC
|
A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation.
Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of ocular itching score over both eyes was analyzed.
|
3, 5, 7 minutes post-CAC
|
Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of conjunctival redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ciliary Redness at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of ciliary redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Episcleral Redness at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of episcleral redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Eyelid Swelling at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe).
Average of eyelid swelling score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Tearing at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of tearing score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Rhinorrhea at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Rhinorrhea score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Nasal Congestion at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Congestion score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Tolerability of Study Medication at Visit 3A
Time Frame: upon instillation, 1 minute and 2 minutes post instillation
|
Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation.
Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
|
upon instillation, 1 minute and 2 minutes post instillation
|
Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of ciliary redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of episcleral redness score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of chemosis score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Chemosis at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of chemosis score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe).
Average of eyelid swelling score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Average of tearing score over both eyes was analyzed.
|
7, 15, 20 minutes post-CAC
|
Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Rhinorrhea score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Pruritus score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Nasal Pruritis at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Pruritus score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe).
Ear or Palate Pruritus score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe).
Ear or Palate Pruritus score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Congestion score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation.
For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity.
Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Composite score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)
Time Frame: 7, 15, 20 minutes post-CAC
|
A treatment efficacy CAC was performed 15 minutes after drop instillation.
For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity.
Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe).
Nasal Composite score for each time point was analyzed.
|
7, 15, 20 minutes post-CAC
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jack Greiner, DO, Charles River Eye Associates
- Principal Investigator: Gail Torkildsen, Andover Eye Associates
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
June 1, 2012
Study Completion (ACTUAL)
June 1, 2012
Study Registration Dates
First Submitted
March 8, 2012
First Submitted That Met QC Criteria
March 8, 2012
First Posted (ESTIMATE)
March 12, 2012
Study Record Updates
Last Update Posted (ACTUAL)
November 7, 2017
Last Update Submitted That Met QC Criteria
October 6, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Hypersensitivity
- Conjunctival Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Cetirizine
Other Study ID Numbers
- 11-100-0012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Conjunctivitis
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedSeasonal Allergic ConjunctivitisChina
-
NovartisAlcon ResearchCompletedSeasonal Allergic ConjunctivitisChina
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisUnited States
-
Eleven BiotherapeuticsCompletedAllergic Conjunctivitis (AC)United States
-
Laboratoires TheaCompletedSeasonal Allergic ConjunctivitisFrance
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic ConjunctivitisSingapore
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
-
Mati Therapeutics Inc.TerminatedSeasonal Allergic Conjunctivitis to RagweedCanada
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
-
Ocular Therapeutix, Inc.ORA, Inc.CompletedChronic Allergic Conjunctivitis
Clinical Trials on AC-170 0.24%
-
Aciex Therapeutics, Inc.Completed
-
Aciex Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aciex Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aciex Therapeutics, Inc.Completed
-
Aciex Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Nicox Ophthalmics, Inc.ORA, Inc.CompletedHealthy SubjectsUnited States
-
Aciex Therapeutics, Inc.CompletedAtopic Disease (Including Allergic Conjunctivitis)United States
-
Curis, Inc.CompletedAdvanced Solid Tumors or LymphomasUnited States, Spain, Korea, Republic of, United Kingdom
-
Toray Industries, IncCompletedCrohn's DiseaseBulgaria, France, Hungary, Belgium, Czech Republic, Latvia, Netherlands, Norway, Poland, Romania, Serbia, Sweden, Ukraine